Schoenberg Mark 4

What Happened

• Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), had restricted stock units (RSUs) convert/exercise on January 31, 2026. The filing shows conversions of 3,333, 6,666 and 3,334 RSU-derived shares (total 13,333 shares) and matching disposals of those same amounts at $0.00 (derivative).
• The Form 4 also records an award/acquisition of 20,000 RSUs (reported at $0.00) that will vest in scheduled installments. The $0.00 disposal entries are consistent with shares being withheld or net-settled (commonly to satisfy withholding taxes), not a cash sale.

Key Details

• Transaction date: January 31, 2026; Form 4 filed February 3, 2026.
• Converted/exercised (derivative M): 3,333 + 6,666 + 3,334 = 13,333 shares acquired and simultaneously 13,333 shares disposed at $0.00.
• Grant/award (A): 20,000 RSUs recorded at $0.00 (see footnotes on vesting).
• Shares owned after transaction: not disclosed in the provided filing details.
• Relevant footnotes:
  • F1: Each RSU represents a contingent right to receive one ordinary share.
  • F2–F4: Schoenberg was granted RSUs on Jan 31, 2023 (10,000), Jan 31, 2024 (10,000) and Jan 31, 2025 (20,000) with multi-year vesting schedules.
  • F5: Vesting schedule examples — 1/3 vesting on Jan 31 of 2027, 2028 and 2029 (per the filing).
• Filing timeliness: filed Feb 3, 2026; no late-filing flag provided in the reported data.

Context

• These are derivative/RSU transactions (not open-market purchases or Section 16 sales). Converting RSUs into shares and having an equal number of shares disposed at $0.00 is typically a net settlement or tax-withholding action rather than an indication of a market sale.
• RSU grants and scheduled vesting are compensation events and routine for executives; purchases (cash buys) usually carry more weight as bullish signals than routine withholding or settlement.